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Abstract 
Background: Betatrophin is a newly identified liver‑derived hormone that is associated with glucose homeostasis 
and lipid metabolism. Although dysregulated lipid metabolism results in diabetic nephropathy (DN) development 
in patients with type 2 diabetes mellitus (T2DM), it is not understood whether betatrophin is associated with urinary 
albumin excretion and renal function.
Methods: Based on albumin/creatinine ratio (ACR), 109 T2DM patients were divided into normoalbuminuria (ACR 
<30 mg/g), microalbuminuria (ACR between 30 and 300 mg/g), and macroalbuminuria (ACR > 300 mg/g). Serum 
betatrophin levels of 109 T2DM patients and 32 healthy subjects were determined by enzyme‑linked immunosorbent 
assay (ELISA).
Results: Serum level of betatrophin was significantly increased in T2DM patients with normoalbuminuria, microalbu‑
minuria, and macroalbuminuria as compared with healthy subjects (P < 0.001). Serum betatrophin level was positively 
correlated with sex, duration of diabetes, systolic blood pressure (SBP), body mass index (BMI), ACR, and triglyceride, 
whereas it was inversely correlated with estimated glomerular filtration rate (eGFR), total cholesterol, and high‑density 
lipoprotein cholesterol (HDL‑C) (P < 0.001). Furthermore, multivariate regression analysis showed the betatrophin was 
significantly and positively independent with triglyceride and low‑density lipoprotein cholesterol (LDL‑C) (P < 0.05), 
whereas it was inversely independent with eGFR, total cholesterol, and low‑density lipoprotein cholesterol (HDL‑C) (P 
< 0.05). In addition, the betatrophin had higher odds of having DN [odds ratio (OR) = 5.65, 95 % confidence interval 
(CI) 2.17–14.57, P < 0.001].
Conclusion: Betatrophin is significantly increased in T2DM patients with different stages of albuminuria. Betatrophin 
may be a novel endocrine regulator involved in DN development.
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Background
Type 2 diabetes mellitus (T2DM) is one of the most 
severe public health problems and affects over 170 mil-
lion people worldwide [1]. The major pathogenesis of 
T2DM is insulin resistance, which is the resistance of 
target tissues to insulin action, and has been suggested 
to play a key role in the cluster of diabetic complications 
including atherosclerosis, and diabetic nephropathy (DN) 
[2, 3]. Recent studies in human autopsy and in a mouse 
model of induced insulin resistance have also suggested 
that patients with T2DM cause insulin resistance due to 
a decrease in β-cell mass by apoptosis [4]. Insulin stim-
ulates albumin gene expression and albumin secretion 
from hepatocyte in both healthy subjects and diabetic 
patients. Reduced serum albumin levels are observed 
in DN, whereas high serum albumin levels have been 
reported to be associated with metabolic syndrome, an 
indicator of obesity and overnutrition [5]. In addition, 
Open Access
Cardiovascular Diabetology
*Correspondence:  chihhong@nctu.edu.tw 
†Chang‑Chiang Chen and Hendra Susanto authors contributed equally 
to this work
1 Department of Biological Science and Technology, National Chiao Tung 
University, 75 Bo‑Ai Street, Hsinchu 300, Taiwan
Full list of author information is available at the end of the article
Page 2 of 9Chen et al. Cardiovasc Diabetol  (2016) 15:3 
recently, serum albumin has been suggested to be asso-
ciated with insulin resistance. The failure of β-cells com-
pensates for ambient insulin resistance that leads to 
uncontrolled hyperglycemia resulted in renal glomerular 
hyperfiltration with microalbuminuria [6]. However, the 
relationship between β-cells and albuminuria or renal 
functions in T2DM patients remains unclear.
Betatrophin is a newly recognized liver-derived hor-
mone that has been implicated in both glucose and lipid 
metabolism [7–9]. Recent study has pointed out that 
mice treated S961 caused insulin resistance resulting in 
β-cell proliferation via overexpressing betatrophin [10]. 
Moreover, serum level of betatrophin is positively asso-
ciated with type 1 Diabetes mellitus (T1DM) and T2DM 
[9, 11, 12], hyperlipidemia [13], and indexes of insulin 
resistance [14]. However, increased levels of betatro-
phin in T1DM is in contradiction with the initial finding 
in an insulin-deficient mouse model by Meltons group 
[11] and there are mixed data regarding betatrophin lev-
els in T2DM. A number of studies reported that betat-
rophin was increased in T2DM patients [4, 8, 12], while 
Gomez-Ambrosi et  al. studies showed that circulating 
betatrophin level was reduced in T2DM patients [15]. 
In addition, mice lacking betatrophin showed a reduc-
tion in plasma triglyceride levels in response to refeeding, 
whereas hepatic overexpression of betatrophin caused 
hypertriglyceridemia without changing glucose metabo-
lism [7]. The circulating concentrations of betatrophin 
are also significantly correlated with atherogenic lipid 
profiles in high-risk cohorts with T2DM or cardiovascu-
lar disease [14]. More recently, Ebert showed that beta-
trophin levels are correlated with clinical renal function 
[16]. Nevertheless, hyperglycemia and altered lipid pro-
file are associated with DN development. It is not clearly 
understood whether betatrophin levels are correlated 
with albuminuria in T2DM.
The aim of this study was to investigate circulating 
betatrophin concentrations in healthy subjects and type 
2 diabetic patients with albuminuria, and to determine 
whether betatrophin levels are associated with DN devel-
opment. We hypothesized that betatrophin concentra-




The study protocol was approved by the Institutional 
Review Board of the National Taiwan University Hospi-
tal Hsin-Chu Branch, Hsinchu, Taiwan (No: 104-001-E). 
The written informed consents were obtained from all 
participants and all studies were carried out in accordance 
with the approved guideline. Participants were enrolled 
between February 2014 and January 2015. All subjects 
were investigated in the morning after an overnight fast. 
A total of 141 Taiwanese subjects were enrolled, of which 
32 were healthy subjects and 109 type 2 diabetes melli-
tus. Among the type 2 diabetic patients, 37 patients had 
normoalbuminuria (ACR < 30  mg/g), 37 had microal-
buminuria (ACR between 30 and 300 mg/g), and 35 had 
macroalbuminuria (ACR > 300  mg/g). The healthy sub-
jects were selected as subjects without disease and not 
taking any medications. Exclusion criteria were as follows: 
(1) any evidence of active infection (e.g. fever, or leuko-
cytosis); (2) any evidence of impaired renal, hepatic, or 
hematopoietic function; (3) no known history of chronic 
systemic diseases, such as diabetes and hypertension; (4) 
no long-term medical treatment for chronic systemic dis-
eases; (5) blood tests showing abnormal glucose levels.
Major metabolic indicators
Blood samples taken after an overnight fast were kept in 
an icebox immediately after collection, and the serum 
was separated from erythrocytes by centrifugation at 
1500×g for 10  min at 4  °C. The serum, if not analyzed, 
was frozen at minus 80  °C within 30  min of collection. 
The estimated glomerular filtration rate (eGFR) was cal-
culated using the simplified modification of diet in renal 
disease (MDRD) study equation.
Laboratory analysis
Blood samples were collected after overnight fasting, and 
serum and urine were stored at minus 20 °C. Serum vari-
ables were analyzed at the Department of Medical and 
Chemical Laboratory Diagnostics at the National Taiwan 
University Hospital Hsin-Chu Branch by using routine pro-
cedures. Serum and urine levels of betatrophin were quan-
tified using a commercially available ELISA kit (Wuhan 
Eiaab Science, Wuhan, China; catalogue No. E11644h) 
according to the manufacturer’s instructions [17]. Current 
ELISA kit was validated against other available kits showing 
correlation coefficient of 0.992. The C-terminal fragment of 
betatrophin was quantified using different human betatro-
phin ELISA kit (Phoenix EK-051-55).
Statistical analysis
All statistical analyses were performed using SPSS Soft-
ware version 21.0 (Chicago, IL, USA). Differences in 
circulating level of betatrophin in healthy subjects and 
T2DM patients with different stages of albuminuria were 
assessed by parametric one-way analysis of variance 
(ANOVA) with Turkey post hoc test. Univariate correla-
tions were performed using non-parametric Spearman’s 
rank correlation method. Afterward, multivariate linear 
regression analysis was performed to identify independ-
ent relationships. Before multivariate correlation analyses 
were calculated, distribution of the respective variables 
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was tested for normality using Kolmogorof-Smirnov test 
and normally distributed parameters were logarithmi-
cally transformed. A P value less than 0.05 was consid-
ered statistically significant.
Results
Baseline characteristics of the total sample
Table  1 summarizes the clinical characteristics of the 4 
groups including healthy subjects, and T2DM patients 
with normoalbuminuria, microalbuminuria and mac-
roalbuminuria. The data revealed that age, duration of 
DM, systolic blood pressure (SBP), body mass index 
(BMI), fasting blood glucose (FBG), albumin to creati-
nine ratio (ACR), hemoglobin A1c (HbA1c), high-sen-
sitivity C-reactive protein (hs-CRP), triglycerides, and 
ACR in T2DM patients with albuminuria had a signifi-
cant increase than in health subjects, whereas eGFR had 
a markedly decrease in T2DM patients with albuminuria 
than in health subjects. There was no statistically sig-
nificant difference between healthy subjects and T2DM 
patients with albuminuria in low-density lipoprotein cho-
lesterol (LDL-C), and total cholesterol levels.
Elevated serum level of betatrophin in T2DM patients 
with albuminuria
Previous study has shown that betatrophin is corre-
lated with renal function [16] and both albumin and 
betatrophin are produced by liver. We also investigated 
whether circulating serum level of betatrophin is asso-
ciated with T2DM patients with albuminuria. We found 
that serum full-length and total betatrophin levels were 
significantly increased in T2DM patients with normoal-
buminuria, microalbuminuria, and macroalbuminuria (P 
< 0.001; Fig. 1a, b) compared with healthy subjects. Both 
full-length and total betatrophin concentrations were 
determined in serum samples by both N-terminal and 
C-terminal kits. Both ELISA kits correlated significantly 
with one another (r = 0.559; P < 0.001; Fig. 1c). We also 
performed betatrophin level in urine samples. Although 
urinary betatrophin level was significantly increased in 
T2DM patients as compared with healthy subjects, it was 
no differences among normoalbuminuria, microalbumi-
nuria, and macroalbuminuria groups (Fig. 1d). Thus, we 
rule out that reduced clearance of betatrophin results in 
decreased glomerular filtration in the different groups. 
Taken together, the data indicates circulating level of 
betatrophin is correlated with T2DM patients with differ-
ent stages of albuminuria and loss of albumin may result 
in increased betatrophin produce.
Univariate correlations of betatrophin in total sample
To investigate whether betatrophin is correlated with 
metabolic parameters, we used Spearman’s correlation. 
As shown by Spearman’s correlation, serum betatrophin 
Table 1 Subject characteristics and metabolic parameters
Data are mean ± SEM
SBP systolic blood pressure, FBG fasting blood glucose, ACR urine albumin/creatinine ratio, % Y % of positive patients with those risk factors of DN
* P < 0.05 vs. healthy subjects, † P < 0.05 vs. normoalbuminuria, ‡ P < 0.05 vs. microalbuminuria
Healthy Normoalbuminuria Microalbuminuria Macroalbuminuria
N 32 37 37 35
Duration of diabetes (years) – 7.6 ± 1.1* 10.6 ± 1.1*† 12.0 ± 1.5*†,‡
Age 50.8 ± 1.2 56.2 ± 1.1* 57.2 ± 0.8* 55.9 ± 1.2*
SBP (mmHg) 100.4 ± 7.3 125.3 ± 4.2* 134.1 ± 3.1* 138.1 ± 2.5*
BMI (kg/m2) 22.7 ± 0.9 25.6 ± 0.5* 26.9 ± 0.5* 27.0 ± 0.8*
Hyperlipidemia (% Y) 0 62.16 72.97 74.28
Hypertension (%) 0 54.05 78.39 82.86
Smoking (% Y) 0 13.51 21.62 25.71
Alcoholism (% Y) 0 13.51 16.21 0
High protein diet (% Y) 0 21.62 24.32 14.28
FBG (mg/dL) 90.97 ± 1.48 142.24 ± 7.09* 157.11 ± 7.10* 153.51 ± 10.04*
eGFR (mL/min/1.73 m2) 93.50 ± 3.07 85.09 ± 3.35 79.89 ± 4.87* 47.65 ± 5.10*,†
ACR (mg/g) 5.7 ± 0.4 12.8 ± 1.2* 100.5 ± 12.4*,† 2229.6 ± 376*,†,‡
HbA1c (%) 5.8 ± 0.1 7.8 ± 0.2* 8.3 ± 0.3* 8.5 ± 0.4*
hsCRP (mg/dL) 0.13 ± 0.01 0.29 ± 0.09* 0.22 ± 0.04* 0.67 ± 0.18*,†,‡
Triglyceride (mg/dL) 118.5 ± 12.1 117.7 ± 14.2 146.5 ± 17.2* 197.6 ± 28.4*,†,‡
LDL cholesterol (mg/dL) 119.1 ± 4.8 109.3 ± 5.9 113.6 ± 5.6 125.5 ± 8.4
HDL cholesterol (mg/dL) 54.9 ± 2.9 55.0 ± 2.3 53.2 ± 3.2* 44.7 ± 1.9*,†,‡
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level in all individuals was positively and significantly cor-
related with duration of DM (r = 0.385, P < 0.001), SBP (r 
= 0.194, P = 0.032), BMI (r = 0.194, P = 0.031), FBG (r = 
0.175, P = 0.048), ACR (r = 0.427, P < 0.001), HbA1C (%) 
(r = 0.264, P = 0.003), and triglycerides (r = 0.282, P = 
0.001) (Table 2). In contrast, betatrophin was significantly 
and inversely correlated with sex (r = −0.331 for male, P 
< 0.001), eGFR (r = −0.454, P < 0.001), total cholesterol 
(r = −0.216, P = 0.018) and high-density lipoprotein cho-
lesterol (HDL-C) (r = −0.391, P < 0.001) (Table 2). After 
correlation for each of the individual groups, we found 
that serum betatrophin level was positively correlated with 
FBG (r = 0.357; P = 0.045 in microalbuminuria group), 
ACR (r = 0.342; P = 0.042 in normoalbuminuria and r = 
0.343; P = 0.049 in microalbuminuria groups), HBA1C (r = 
0.361; P = 0.045 in microalbuminuria group) and triglyc-
eride (r = 0.368; P = 0.042 in microalbuminuria group). 
Its level was inversely correlated with age (r = −0.362; P 
= 0.033 in macroalbuminuria group), sex (r = −0.485; P 
= 0.008 in healthy group, and r = −0.530; P = 0.003 in 
microalbuminuria group), eGFR (r = −0.375; P = 0.024 
in normoalbuminuria group, and r = −0.435; P = 0.018 in 
microalbuminuria group), total cholesterol (r = −0.434; P 
= 0.019 in microalbuminuria group), and HDL-cholesterol 
(r = −0.593; P < 0.001 in microalbuminuria group, and r = 
−0.446; P = 0.007 in macroalbuminuria group).
Multivariate regression analysis in the total sample
To verify independent associations, multiple lin-
ear regression analysis was performed. The eGFR 
Fig. 1 Serum and urine betatrophin concentrations of healthy and T2DM patients with normoalbuminuria, microalbuminuria and macroalbumi‑
nuria. a Serum full‑length betatrophin level was measured by N‑terminal kit and b serum total betatrophin level was measured by C‑terminal kit. c 
Correlations between N‑terminal kit and C‑terminal kit. d Urinary betatrophin level was measured by N‑terminal kit. Data are mean ± SEM. *P < 0.05 
vs. healthy subjects; †P < 0.05 vs. normoalbuminuria; ‡P < 0.05 vs. microalbuminuria
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showed an independent and significant predictor of 
betatrophin (P < 0.05; Table 3). Furthermore, circulat-
ing level of betatrophin was significantly and positively 
independent with triglyceride, and LDL-C (P < 0.05), 
whereas it was inversely independent with total cho-
lesterol (P < 0.05; Table 3).
Betatrophin versus DN risk factors
DN risks including duration of DM, hypertension, 
hyperlipidemia, smoking, and high protein diet have 
been addressed. We next investigated whether betatro-
phin is associated with duration of DM, hypertension, 
hyperlipidemia, smoking, and high protein diet of T2D 
with albuminuria. The data showed that the serum beta-
trophin level was significantly increased in the type 2 
diabetic patients with >5  years duration of DM, hyper-
tension, hyperlipidemia, and smoking, but there was no 
significant difference of betatrophin level in patients who 
consumed alcohol or had a high protein diet (Fig. 2).
Betatrophin versus nephropathy
When the betatrophin was related to DN (ACR > 
300  mg/g) in a multivariate binary logistic regression 
model, serum level of betatrophin was significantly 
related to DN [odds ratio (OR) 5.63 (95 % CI 2.17–14.57), 
P < 0.001] (Table 4) without adjustment. Following mul-
tiple adjustment with Age, sex, and BMI, we observed 
that the OR for hsCRP was significantly related to DN 
[2.73 (95 % CI 1.11–6.72), P = 0.029], while betatrophin 
had the highest OR and was significantly related to DN 
[OR 5.65 (95 % CI 2.17–14.57), P < 0.001] (Table 4). This 
result suggests that betatrophin may serve as predictor 
of DN.
Table 2 Univariate correlations of  parameters with  serum betatrophin level in  all participants, and  T2DM patients 
with normoalbuminuria, microalbuminuria, and macroalbuminuria
SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, FBG fasting blood glucose, ACR albumin /creatinine ratio, eGFR estimated glomerular 
filtration rate, HbA1c hemoglobin A1c, hsCRP high sensitive C-reactive protein, r coefficient correlation
* P value <0.05 significant correlation as assessed by Spearman’s correlation method
Parameters All participants r  
(P value)








Age (years) 0.131 (0.145) −0.108 (0.960) −0.123 (0.476) 0.278 (0.145) −0.362 (0.033*)
Sex (Male/Female) −0.331 (<0.001*) −0.485 (0.008*) 0.086 (0.625) −0.530 (0.003*) −0.278 (0.105)
DM duration (years) 0.385 (<0.001*) – 0.183 (0.292) −0.392 (0.035*) 0.009 (0.960)
SBP (mmHg) 0.194 (0.032*) 0.113 (0.583) 0.040 (0.821) 0.104 (0.592) −0.166 (0.342)
DBP (mmHg) 0.141 (0.122) −0.012 (0.955) 0.167 (0.346) 0.281 (0.140) −0.324 (0.057)
BMI (kg/m2) 0.194 (0.031*) 0.010 (0.961) 0.105 (0.550) 0.025 (0.897) 0.192 (0.269)
FBG (mg/dL) 0.175 (0.048*) −0.002 (0.993) −0.040 (0.819) 0.357 (0.045*) −0.076 (0.663)
ACR (mg/g) 0.427 (<0.001*) −0.180 (0.359) 0.342 (0.042*) 0.343 (0.049*) 0.025 (0.890)
eGFR (ml/min/1.73 m2) −0.454 (<0.001*) −0.108 (0.578) −0.375 (0.024*) −0.435 (0.018*) −0.239 (0.166)
HbA1c (%) 0.264 (0.003*) 0.169 (0.380) 0.289 (0.077) 0.361 (0.045*) −0.127 (0.469)
hsCRP (mg/dL) 0.133 (0.138) −0.108 (0.578) 0.009 (0.959) −0.208 (0.278) −0.135 (0.438)
Triglyceride (mg/dL) 0.282 (0.001*) 0.184 (0.338) −0.222 (0.200) 0.368 (0.042*) 0.224 (0.196)
Total Cholesterol (mg/dL) −0.261 (0.001*) 0.102 (0.599) 0.176 (0.313) −0.434 (0.019*) −0.192 (0.270)
LDL cholesterol (mg/dL) 0.017 (0.853) 0.027 (0.889) 0.236 (0.172) −0.278 (0.144) −0.027 (0.880)
HDL cholesterol (md/dL) −0.391 (<0.001*) −0.293 (0.130) 0.132 (0.449) −0.593 (<0.001*) −0.446 (0.007*)
Table 3 Multivariate regression analysis with  betatrophin 
as dependent variable
Multivariate regression analysis between betatrophin (dependent variable) and 
independent variables shown
Independent variables
Standardized β-coefficients and P value are given
* P < 0.05 is significant correlation
Independent variables β (95 % CI) P
Age −0.008 (−0.025 to 0.008) 0.324
Sex −0.207 (−0.436 to 0.022) 0.076
Duration of diabetes 0.003 (−0.014 to 0.019) 0.748
SBP 0.002 (−0.005 to 0.008) 0.596
BMI −0.002 (−0.032 to 0.027) 0.888
FBG 0.000 (−0.003 to 0.003) 0.915
eGFR (ml/min/1.73 m2) −0.005 (−0.010 to 0.001) 0.039
ACR 6.875 (0.000 to 0.000) 0.443
HbA1c (%) 0.038 (−0.040 to 0.116) 0.338
hsCRP −0.063 (−0.205 to 0.079) 0.383
Triglyceride 0.001 (0.000 to 0.003) 0.036*
LDL cholesterol 0.005 (0.000 to 0.009) 0.049*
HDL cholesterol 0.001 (−0.008 to 0.010) 0.832
Total cholesterol −0.005 (−0.010 to 0.000) 0.026*
Page 6 of 9Chen et al. Cardiovasc Diabetol  (2016) 15:3 
Discussion
In this study, we show that serum level of betatrophin 
was significantly increased in T2DM patients with nor-
moalbuminuria, microalbuminuria, and macroalbumi-
nuria compared with healthy subjects (P < 0.001), in 
particular macroalbuminuric type 2 diabetic patients. 
Furthermore, serum level of betatrophin was posi-
tively correlated with duration of DM, SBP, BMI, FBG, 
HbA1C, ACR, and triglyceride, whereas it was inversely 
correlated with eGFR, and HDL-C (P < 0.001). However, 
after correlation for each of the individual groups, we 
found that serum betatrophin level was positively cor-
related with FBG, ACR, HBA1C, and triglyceride, while 
its level was inversely correlated with sex, eGFR, total 
cholesterol, and HDL-cholesterol in microalbuminu-
ria group. Importantly, we found that betatrophin had 
higher odds of having DN progression. Thus, betatro-
phin may be a novel endocrine regulator involved in DN 
development.
Increased serum betatrophin level in T2DM patients
Betatrophin has been suggested a liver-derived hor-
mone that is capable of inducing β-cell proliferation by 
Yi et al. [10], and a number of studies showed that betat-
rophin upregulated in T2DM patients [12, 18, 19], while 
Gomez-Ambrosi et  al. studies showed that circulating 
betatrophin level was reduced in T2DM patients [15]. 
In addition, loss of albumin in urine has been implicated 
insulin resistance, which causes liver produced hor-
mones as potential mediators of the increased β-cell pro-
liferation in T2DM [6, 20]. However, it is still unknown 
whether loss of albumin in urine causes increased serum 
betatrophin level or not. In the current study, our data in 
agreement with previous studies that serum level of beta-
trophin was increased in T2DM patients as compared 
with healthy subjects, especially in macroalbuminuria 
group. This increase may be related to loss of albumin 
causing increased insulin resistance and higher demand 
for insulin in T2DM patients with albuminuria. Impor-
tantly, we found a significant association between betat-
rophin and glucose or HbA1c. Recent studies have shown 
that betatrophin levels was up-regulated by 3–4 folds at 
the transcription level in the liver of the db/db and ob/ob 
mice models as compared with wild-type mice [10]. This 
trend in increased betatrophin level was also observed in 
patients with longer duration of T2DM in our population 
Fig. 2 Serum level of betatrophin is associated with the risk factor of DN. a Duration of DM, b hypertension, c hyperlipidemia, d smoking, e alcohol, 
and f high protein diet. Data are shown as mean ± SEM. *P < 0.05 and ns not significant
Page 7 of 9Chen et al. Cardiovasc Diabetol  (2016) 15:3 
[4, 8]. However, there are mixed data regarding betatro-
phin level in T2DM studies. A recent report found that 
betatrophin level was reduced in T2DM patients [15]. 
Fu et al. suggested that the discrepancies were caused by 
different sample size, BMI, and ethnic groups in T2DM 
[21]. Therefore, role of betatrophin in T2DM is need to 
elucidate in future studies.
Effect of age and BMI on the betatrophin level
There are several factors affect circulating betatrophin 
level including age and BMI. Abu-Farha M et al. studies 
have reported that betatrophin level was not associ-
ated with T2DM [22, 23] and age may affect this results. 
In the present study, we observed that serum betatro-
phin level was inversely correlated with age in T2DM 
patients with macroalbuminuria group. Age has related 
to mitochondria dysfunction, increased oxidative stress, 
inflammation, and hormonal changes [24], which play an 
important role in the pathogenesis of DN progression. 
Moreover, we found that BMI was significantly increased 
in T2DM patients as compared with healthy subjects. 
In agreement with our findings, increased expression of 
the betatrophin has been shown in T2DM patients with 
higher BMI [12], and in obese individuals [25]. Ebert 
et  al. have also demonstrated that insulin is a direct 
dose-and time-dependent to induce betatrophin mRNA 
expression in differentiated 3T3-L1 adipocytes in  vitro 
[16]. Thus, fat tissue and its adipokines may affect betat-
rophin expression and secretion from hepatocytes. Thus, 
we can not rule out the factors age, and BMI resulting in 
increased circulating betatrophin level in T2DM patients 
with albuminuria in our study.
Serum lipids is correlated with betatrophin and potentially 
contributes to progression of DN
It is known that dyslipidemia potentially contributes 
to progression of DN [26, 27]. Recent studies have 
confirmed a link between serum lipids and DN [28]. 
Importantly, several studies reported that triglycer-
ides and cholesterol have different effects on the pro-
gression of nephropathy, depending upon the duration 
of diabetes [29, 30]. Accumulation of lipids in kidney 
causes increased advanced glycation end-products 
(AGEs), inflammatory cytokines, and reactive oxygen 
species (ROS) resulted in endothelial dysfunction, glo-
merulosclerosis and tubulointerstitial injury in T2DM 
[31–33]. In this study, the multivariate regression 
analysis showed serum betatrophin level was a positive 
and independent predictor of DN. Its level was signifi-
cantly and positively independent with triglyceride (P < 
0.05), whereas it was inversely independent with eGFR, 
total cholesterol, and HDL-C (P < 0.05). DN has been 
characterized by persistent albuminuria (>300  mg/g) 
and progressive decline in the eGFR. DN causes albu-
min loss in urine resulted in reduced serum albumin. 
Serum albumin levels have been associated with lipid 
metabolism. The primary role of albumin is to trans-
port fatty acids to liver. Betatrophin is known to play 
a key role in lipid metabolism [14, 34] and our study 
show that serum betatrophin level was significantly 
associated with triglyceride and LDL-C (P < 0.05). In 
agreement with our findings, mice lacking betatro-
phin had a 70  % reduction in plasma levels of triglyc-
erides compared to wild-type control mice [7], whereas 
Table 4 OR (95 % CI) by binary logistic regression models 
for nephropathy with ACR as dependent variable
Model 1 unadjusted, Model 2 age adjusted, Model 3 sex adjusted, Model 4 BMI 
adjusted, Model 5 age, sex, and BMI adjusted, hsCRP high sensitive C-reactive 
protein, SBP systolic blood pressure, HbA1c hemoglobin A1c, TG triglycerides
* P < 0.05 is significant in all model
Models Covariates ACR (n = 141)
Normal (n = 106) Nephropathy (n = 35)
OR (95 % CI) P OR (95 % CI) P
Model 1 Betatrophin 1.00 – 5.63 (2.17–14.57) <0.001*
DM duration 1.00 – 1.08 (1.00–1.15) 0.040*
hsCRP 1.00 – 1.91 (0.91–3.98) 0.086
SBP 1.00 – 1.03 (0.99–1.06) 0.103
HbA1c 1.00 – 1.11 (0.86–1.44) 0.434
TG 1.00 – 1.00 (0.99–1.01) 0.092
Model 2 Betatrophin 1.00 – 6.36 (2.78–14.55) <0.001*
DM duration 1.00 – 1.09 (1.03–1.16) 0.002*
hsCRP 1.00 – 2.90 (1.17–7.20) 0.022*
SBP 1.00 – 1.03 (1.01–1.06) 0.012*
HbA1c 1.00 – 1.27 (1.03–1.56) 0.026*
TG 1.00 – 1.01 (1.00–1.01) 0.005*
Model 3 Betatrophin 1.00 – 5.79 (2.51–13.32) <0.001*
DM duration 1.00 – 1.10 (1.05–1.17) <0.001*
hsCRP 1.00 – 3.19 (1.28–7.97) 0.013*
SBP 1.00 – 1.04 (1.01–1.06) 0.004*
HbA1c 1.00 – 1.33 (1.08–1.64) 0.007*
TG 1.00 – 1.01 (1.00–1.01) 0.006*
Model 4 Betatrophin 1.00 – 5.43 (2.44–12.09) <0.001*
DM duration 1.00 – 1.10 (1.04–1.16) 0.001*
hsCRP 1.00 – 2.44 (1.10–5.43) 0.029*
SBP 1.00 – 1.03 (1.01–1.06) 0.010*
HbA1c 1.00 – 1.28 (1.04–1.56) 0.018*
TG 1.00 – 1.00 (1.00–1.01) 0.014*
Model 5 Betatrophin 1.00 – 5.65 (2.39–13.33) <0.001*
DM duration 1.00 – 1.10 (1.03–1.16) 0.002*
hsCRP 1.00 – 2.73 (1.11–6.72) 0.029*
SBP 1.00 – 1.03 (1.00–1.06) 0.021*
HbA1c 1.00 – 1.26 (1.01–1.56) 0.036*
TG 1.00 – 1.01 (1.00–1.01) 0.017*
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adenovirus-mediated hepatic overexpression of beta-
trophin increased plasma triglyceride levels more 
than fivefold [35]. Moreover, Fenzl et  al. found that 
serum betatrophin level was associated with triglycer-
ides, HDL-C, and apolipoprotein B in type 2 diabetic 
patients [14]. Thus, dysregulated lipid metabolism may 
be the potential mechanism involved betatrophin in the 
development of DN. Moreover, we also observed beta-
trophin was inversely correlated with eGFR, whereas 
previous studies showed serum level of betatrophin 
has a positive associated with eGFR in T2DM patients 
with hemodialysis [16]. The disparities may be simply 
due to the samples from chronic kidney disease with 
hemodialysis, not T2DM with albuminuria. Hemodi-
alysis is a process that uses a man-made membrane to 
remove wastes, such as urea and albumin from blood, 
and restore the proper balance of electrolytes in the 
blood. The patients with chronic kidney disease need 
three times a week for hemodialysis and may remove 
the inducers of betatrophin in blood. However, future 
studies are needed to elucidate this speculation.
Conclusions
Taken together, our results show that circulating betatro-
phin concentrations were significantly increased in type 
2 diabetic patients with different stages of albuminuria, 
in particular macroalbuminuric type 2 diabetic patients. 
Furthermore, betatrophin was correlated with duration 
of DM, SBP, BMI, FBG, HbA1C, ACR, and triglyceride, 
whereas it was inversely correlated with eGFR, and HDL-
C. Dysregulated lipid metabolism may be the potential 
mechanism involved betatrophin in the development of 
DN. Thus, betatrophin may be a novel endocrine regula-
tor involved in DN development. Further studies need to 
elucidate factors contributing to betatrophin regulation 
in humans as well as the pathophysiological significance 
of betatrophin upregulation in DN.
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